{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:04Z","timestamp":1793159104575,"version":"4.5.0"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tomography"],"abstract":"<jats:p>Background: The usefulness of monitoring treatment effect of tafamidis using magnetic resonance imaging (MRI) extracellular volume fraction (ECV) has been reported. Objective: we conducted a meta-analysis to evaluate the usefulness of this method. Methods: Data from 246 ATTR-CMs from six studies were extracted and included in the analysis. An inverse variance meta-analysis using a random effects model was performed to evaluate the change in MRI-ECV before and after tafamidis treatment. The analysis was also performed by classifying the patients into ATTR-CM types (wild-type or hereditary). Results: ECV change before and after tafamidis treatment was 0.33% (95% CI: \u22121.83\u20132.49, I2 = 0%, p = 0.76 for heterogeneity) in the treatment group and 4.23% (95% CI: 0.44\u20138.02, I2 = 0%, p = 0.18 for heterogeneity) in the non-treatment group. The change in ECV before and after treatment was not significant in the treated group (p = 0.76), but there was a significant increase in the non-treated group (p = 0.03). There was no difference in the change in ECV between wild-type (95% CI: \u22122.65\u20133.40) and hereditary-type (95% CI: \u22129.28\u20134.28) (p = 0.45). Conclusions: The results of this meta-analysis suggest that MRI-ECV measurement is a useful imaging method for noninvasively evaluating the efficacy of tafamidis treatment for ATTR-CM.<\/jats:p>","DOI":"10.3390\/tomography10080097","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T12:40:07Z","timestamp":1723812007000},"page":"1303-1311","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Monitoring the Efficacy of Tafamidis in ATTR Cardiac Amyloidosis by MRI-ECV: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7545-0669","authenticated-orcid":false,"given":"Shingo","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Diagnostic Radiology, Graduate School of Medicine, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Azuma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-Higashi, Kanazawa-ku, Yokohama 236-0051, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[{"name":"Chemotherapy Center, Yokohama City University Hospital, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Graduate School of Medicine, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: An update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial Biopsy Characterization of Heart Failure with Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Narotsky","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e016614","DOI":"10.1161\/JAHA.120.016614","article-title":"Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations","volume":"9","author":"Marques","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jcmg.2023.10.010","article-title":"Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy","volume":"17","author":"Alwan","year":"2024","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: A comprehensive review","volume":"18","author":"Haaf","year":"2016","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","article-title":"Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis","volume":"13","author":"Pan","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_12","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00392-022-02035-w","article-title":"Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging","volume":"112","author":"Chamling","year":"2023","journal-title":"Clin. Res. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/ehf2.14380","article-title":"Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy","volume":"10","author":"Takashio","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"iii-173","DOI":"10.3310\/hta7270","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technol. Assess."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR Derived Extracellular Volume with Patisiran Indicates Cardiac Amyloid Regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13023-023-02824-0","article-title":"Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: A 12-month follow-up cohort study","volume":"18","author":"Tsai","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ney, S., Gertz, R.J., Pennig, L., Nies, R.J., Holtick, U., V\u00f6lker, L.A., Wunderlich, G., Seuthe, K., Hohmann, C., and Metze, C. (2024). Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010284"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"131598","DOI":"10.1016\/j.ijcard.2023.131598","article-title":"Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States","volume":"398","author":"Lau","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2459\/JCM.0000000000001036","article-title":"Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation","volume":"21","author":"Gospodinova","year":"2020","journal-title":"J. Cardiovasc. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","article-title":"Early Experience of Tafamidis Treatment in Japanese Patients with Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis Cohort","volume":"86","author":"Ochi","year":"2022","journal-title":"Circ. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102172","DOI":"10.1016\/j.eclinm.2023.102172","article-title":"Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: A systematic review and meta-analysis","volume":"63","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jmri.1052","article-title":"Measurement of left ventricular dimensions and function in patients with dilated cardiomyopathy","volume":"13","author":"Strohm","year":"2001","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid","volume":"389","author":"Donal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to Image Cardiac Amyloidosis: A Practical Approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jcmg.2023.03.021","article-title":"Cardiac Computed Tomography for Quantification of Myocardial Extracellular Volume Fraction: A Systematic Review and Meta-Analysis","volume":"16","author":"Han","year":"2023","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jcmg.2023.10.008","article-title":"Clinical Utility of Computed Tomography-Derived Myocardial Extracellular Volume Fraction: A Systematic Review and Meta-Analysis","volume":"17","author":"Kato","year":"2024","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8464","DOI":"10.1007\/s00330-023-09872-x","article-title":"CT for the evaluation of myocardial extracellular volume with MRI as reference: A systematic review and meta-analysis","volume":"33","author":"Zhang","year":"2023","journal-title":"Eur. Radiol."}],"container-title":["Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2379-139X\/10\/8\/97\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:37:56Z","timestamp":1760110676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2379-139X\/10\/8\/97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["tomography10080097"],"URL":"https:\/\/doi.org\/10.3390\/tomography10080097","relation":{},"ISSN":["2379-139X"],"issn-type":[{"value":"2379-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}